Ding Yuanjie, Ma Qing, Liu Fen, Zhao Lei, Wei Wenqiang
Department of Epidemiology and Health Statistics, School of Public Health, Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, China.
Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
PLoS One. 2016 Nov 10;11(11):e0166303. doi: 10.1371/journal.pone.0166303. eCollection 2016.
Accumulating evidence has demonstrated that microRNAs (miRNAs) could serve as promising molecular biomarkers for cancer detection. This study aims to systematically assess the diagnostic performance of salivary miRNAs in detection of cancer through a comprehensive meta-analysis.
Eligible studies were identified using PubMed and other computerized databases up to October 31, 2015, supplemented by a manual search of references from retrieved articles. The pooled sensitivity, specificity, and other measurements of accuracy of salivary miRNAs in the diagnosis of cancer were analyzed using the bivariate binomial mixed model.
Seventeen studies from 8 articles with 694 subjects were included in this meta-analysis. All studies have a relatively high score of quality assessment. The overall sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of salivary miRNAs in detection of cancer were 0.77 (95% confidence intervals [CI]: 0.69-0.84), 0.77 (95%CI: 0.65-0.88), 3.37 (95%CI: 2.26-5.02), 0.29 (95%CI: 0.23-0.38), and 11.41 (95%CI: 7.35-17.73), respectively. The AUC was 0.84 (95%CI: 0.80-0.87). Moreover, both whole saliva and saliva supernatant could be used as sources of clinical specimens for miRNAs detection.
Our meta-analysis demonstrated that salivary miRNAs may serve as potential noninvasive biomarkers for cancer detection. The findings need to be confirmed with further research before it can be applied in the clinic.
越来越多的证据表明,微小RNA(miRNA)可作为有前景的癌症检测分子生物标志物。本研究旨在通过全面的荟萃分析系统评估唾液miRNA在癌症检测中的诊断性能。
使用PubMed和其他计算机数据库检索截至2015年10月31日的合格研究,并通过手动检索所获文章的参考文献进行补充。采用双变量二项混合模型分析唾液miRNA诊断癌症的合并敏感性、特异性及其他准确性测量指标。
本荟萃分析纳入了8篇文章中的17项研究,共694名受试者。所有研究的质量评估得分相对较高。唾液miRNA检测癌症的总体敏感性、特异性、阳性似然比(PLR)、阴性似然比(NLR)和诊断比值比(DOR)分别为0.77(95%置信区间[CI]:0.69 - 0.84)、0.77(95%CI:0.65 - 0.88)、3.37(95%CI:2.26 - 5.02)、0.29(95%CI:0.23 - 0.38)和11.41(95%CI:7.35 - 17.73)。曲线下面积(AUC)为0.84(95%CI:0.80 - 0.87)。此外,全唾液和唾液上清液均可作为检测miRNA的临床标本来源。
我们的荟萃分析表明,唾液miRNA可能作为癌症检测的潜在非侵入性生物标志物。这些发现需要进一步研究证实后才能应用于临床。